Tumor Biology

, Volume 35, Issue 8, pp 7383–7389 | Cite as

Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis

  • Hao Jiang
  • Wei Zhao
  • Wei Shao


We sought to clarify the prognostic value of CD44 in survival of patients with non-small cell lung cancer (NSCLC). We performed a meta-analysis of relevant literature to aggregate the available survival results, using studies published in English until March 2014. Eligible studies dealt with CD44, CD44 standard form (CD44s) and CD44 variant 6 (CD44v6), assessment in NSCLC patients on primary lesions and reported survival data according to CD44 and CD44 isoforms expression. We aggregated 10 trials (5 trials for CD44v6, 3 trials for CD44, and 2 trials for CD44s) comprising 1,074 patients, in this meta-analysis. The combined hazard ratio (HR) with CD44v6 and CD44s was 2.39 (95 % confidence interval (CI) 1.69–3.37) and 1.64 (95 % CI 1.06–2.52), respectively. It associated high CD44v6 and CD44s expression with poor survival in NSCLC patients. However, CD44 overexpression did not significantly correlate with survival in patients with NSCLC (HR 1.44; 95 % CI 0.72–2.89). Our meta-analysis shows that CD44v6 and CD44s overexpression indicates poor prognosis for NSCLC patients. However, the high CD44 expression is not significantly correlated with survival for patients with NSCLC.


CD44 CD44v6 Non-small cell lung cancer Prognosis Meta-analysis Hazard ratio 



Wei Zhao and Wei Shao extracted data from eligible studies independently, discussed discrepancies, and reached at least 95 % agreement on all criteria used. Any remaining disagreements were resolved through discussion with the primary investigators or arbitration by a third reviewer (Hao Jiang).

Conflicts of interest

The authors declare that they have no conflict of interest. We declare that we have no financial, professional, or personal relationships with people, organizations, services, or products that inappropriately influence our work or that could be construed as influencing positions presented in this article.


  1. 1.
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.PubMedCrossRefGoogle Scholar
  2. 2.
    Jett JR, Scott WJ, Rivera MP, Sause WT. American College of Chest Physicians. Guidelines on treatment of stage IIIB nonsmall cell lung cancer. Chest. 2003;123:221S–5S.PubMedCrossRefGoogle Scholar
  3. 3.
    Alberg A, Ford J, Samet J. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines. Chest. 2007;132:29S–55S.PubMedCrossRefGoogle Scholar
  4. 4.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Gunthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Wang SJ, Wong G, De Heer AM, Xia W. Bourguignon LY.CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope. 2009;119:1518–30.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Yamada Y, Itano N, Narimatsu H, Kudo T, Hirohashi S, Ochiai A, et al. CD44 variant exon 6 expressions in colon cancer assessed by quantitative analysis using real time reverse transcriptase-polymerase chain reaction. Oncol Rep. 2003;10:1919–24.PubMedGoogle Scholar
  8. 8.
    Afify AM, Craig S, Paulino AF, Stern R. Expression of hyaluronic acid and its receptors, CD44s and CD44v6, in normal, hyperplastic, and neoplastic endometrium. Ann Diagn Pathol. 2005;9:312–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Afify AM, Ferguson AW, Davila RM, Werness BA. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Appl Immunohistochem Mol Morphol. 2001;9:309–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Dong WG, Sun XM, Yu BP, Luo HS, Yu JP. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol. 2003;9:2596–600.PubMedGoogle Scholar
  11. 11.
    Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–71.PubMedCrossRefGoogle Scholar
  14. 14.
    Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Clarke MR, Landreneau RJ, Resnick NM, Crowley R, Dougherty GJ, Cooper DL, et al. Prognostic significance of CD44 expression in adenocarcinoma of the lung. J Clin Pathol Mol Pathol. 1995;48:M200–4.CrossRefGoogle Scholar
  16. 16.
    Leung ELH, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLos One. 2010;5:e14062. doi: 10.1371/journal.pone.0014062.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Sterlacci W, Savic S, Fiegl M, Obermann E, Tzankov A. Putative stem cell markers in non–small-cell lung cancer a clinicopathologic characterization. J Thorac Oncol. 2014;9:41–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Takanami I, Takeuchi K, Naruke M. Expression and prognostic value of the standard CD44 protein in pulmonary adenocarcinoma. Oncol Rep. 2000;7:1065–7.PubMedGoogle Scholar
  19. 19.
    Ko YH, Won HS, Jeon EK, Hong SH, Roh SY, Hong YS, et al. Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer. 2011;11:340.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Hirata T, Fukuse T, Naiki H, Hitomi S, Wada H. Expression of CD44 variant Exon 6 in stage I non-small cell lung carcinoma as a prognostic factor. Cancer Res. 1998;58:1108–10.PubMedGoogle Scholar
  21. 21.
    Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H. Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases. Cancer. 1999;86:1174–81.PubMedCrossRefGoogle Scholar
  22. 22.
    Ramasami S, Kerr KM, Chapman AD, King G, Cockburn JS, Jeffrey RR. Expression of CD44v6 but not E-cadherin or b-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol. 2000;192:427–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Situ D, Long H, Lin P, Zhu Z, Wang J, Zhang X, et al. Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma. J Cancer Res Clin Oncol. 2010;136:1213–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Sun BS, Li Y, Zhang ZF, Wang CL. Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg. 2013;96:1943–51.PubMedCrossRefGoogle Scholar
  25. 25.
    Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997;71:241–319.PubMedCrossRefGoogle Scholar
  26. 26.
    Shimada Y, Ishii G, Nagai K, Atsumi N, Fujii S, Yamada A, et al. Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci. 2009;100:2054–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Tran TA, Kallakury BV, Sheehan CE, Ross JS. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum Pathol. 1997;28:809–14.PubMedCrossRefGoogle Scholar
  28. 28.
    Pirinen R, Hirvikoski P, Böhm J, Kellokoski J, Moisio K, Virén M, et al. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma. Hum Pathol. 2000;3:1088–95.CrossRefGoogle Scholar
  29. 29.
    Nguyen VN, Mirejovský T, Melinová L, Mandys V. CD44 and its v6 spliced variant in lung carcinomas: relation to NCAM, CEA, EMA and UP1 and prognostic significance. Neoplasma. 2000;47:400–8.PubMedGoogle Scholar
  30. 30.
    Carbognani P, Spaggiari L, Romani A, Solli P, Corradi A, Cantoni AM, et al. Expression of human CD44v6 in non-small-cell lung cancer. Eur Surg Res. 1998;30:403–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non -small cell lung cancers. Clin Cancer Res. 2006;12:1507–14.PubMedCrossRefGoogle Scholar
  32. 32.
    Eren B, Sar M, Oz B, Dincbas FH. MMP-2, TIMP-2 and CD44v6 expression in non-small-cell lung carcinomas. Ann Acad Med Singap. 2008;37:32–9.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Respiratory MedicineThe Second Affiliated Hospital, Southeast UniversityJiangsuPeople’s Republic of China
  2. 2.Department of OncologyThe Second Affiliated Hospital, Southeast UniversityJiangsuPeople’s Republic of China
  3. 3.Department of Emergency MedicineThe Second Affiliated Hospital, Southeast UniversityJiangsuPeople’s Republic of China

Personalised recommendations